GoodRx Holdings, Inc. Net Income (Loss) Available to Common Stockholders, Basic
GoodRx Holdings, Inc. (GDRX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$25.25 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-03-01
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$39.91M.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$18.07M.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was $31.06M, a 75.85% increase year-over-year.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was $1.67M, a 90.56% decline year-over-year.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$25.25M.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$293.62M, a 791.84% decline from fiscal 2019.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was $42.44M, a 207.65% increase from fiscal 2018.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was $13.79M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$39.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$57.98M derived: sum of 2 quarters · filed 2022-03-01 | -$26.92M derived: sum of 3 quarters · filed 2022-03-01 | -$25.25M 10-K · filed 2022-03-01 |
| 2021-09-30 | -$18.07M 10-Q · filed 2021-11-12 | $12.99M derived: sum of 2 quarters · filed 2021-11-12 | $14.66M 10-Q · filed 2021-11-12 | -$282.01M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-06-30 | $31.06M 10-Q · filed 2021-08-12 | $32.73M 10-Q · filed 2021-08-12 | -$263.94M derived: sum of 3 quarters · filed 2022-03-01 | -$313.97M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | $1.67M 10-Q · filed 2021-05-14 | -$295.00M derived: sum of 2 quarters · filed 2022-03-01 | -$345.03M derived: sum of 3 quarters · filed 2022-03-01 | -$327.37M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | -$296.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$346.70M derived: sum of 2 quarters · filed 2022-03-01 | -$329.04M derived: sum of 3 quarters · filed 2022-03-01 | -$293.62M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$50.03M 10-Q · filed 2021-11-12 | -$32.37M derived: sum of 2 quarters · filed 2021-11-12 | $3.04M 10-Q · filed 2021-11-12 | -$4.90M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $17.66M 10-Q · filed 2021-08-12 | $35.33M 10-Q · filed 2021-08-12 | $45.13M derived: sum of 3 quarters · filed 2022-03-01 | $57.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $17.66M 10-Q · filed 2021-05-14 | $27.46M derived: sum of 2 quarters · filed 2022-03-01 | $40.08M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $22.42M derived: sum of 2 quarters · filed 2022-03-01 | $42.44M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $12.62M 10-Q · filed 2020-11-12 | $32.64M 10-Q · filed 2020-11-12 | ||
| 2018-12-31 | $13.79M 10-K · filed 2021-03-12 |